Literature DB >> 884390

Possible mechanism of adverse reaction following levodopa plus benserazide treatment.

F S Messiha.   

Abstract

1 Rats treated for seven days with seryl-trihydroxybenzylhydrazine (benserazide), and inhibitor of peripheral aromatic L-amino acid decarboxylase (500 mg/kg, daily, i.p.) alone or in combination with L-DOPA methylester (500 mg/kg, daily, i.p.) for seven days showed a moderate but significant decrease of liver aldehyde dehydrogenase (ALDH), without accompanying change in alcohol dehydrogenase (ADH) activity, compared with saline-treated controls. 2 Administration of L-DOPA methylester (500 mg/kg, daily, i.p.) alone for seven days had little effect on liver ADH or ALDH. 3. The combined treatment might be conducive to the in vivo formation of L-DOPA-derived tetrahydroisoquinoline derivatives which might be implicated in L-DOPA produced adverse effects.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 884390      PMCID: PMC1667174          DOI: 10.1111/j.1476-5381.1977.tb16746.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Effects of several catecholamine-derived tetrahydroisoquinolines on the hypogastric nerve-vas deferens preparation of the rat.

Authors:  J Baird-Lambert; G Cohen
Journal:  J Pharm Pharmacol       Date:  1975-12       Impact factor: 3.765

2.  INHIBITION OF DECARBOXYLASE OF AROMATIC AMINO ACIDS BY 2,3,4-TRIHYDROXYBENZYLHYDRAZINE AND ITS SERYL DERIVATIVE.

Authors:  W P BURKARD; K F GEY; A PLETSCHER
Journal:  Arch Biochem Biophys       Date:  1964-08       Impact factor: 4.013

3.  [PHARMACOLOGY OF TETRAHYDROPAPAVEROLINE AND ITS FORMATION FROM DOPAMINE].

Authors:  P HOLTZ; K STOCK; E WESTERMANN
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1964-07-20

4.  Human liver aldehyde dehydrogenase: partial purification and properties.

Authors:  A H Blair; F H Bodley
Journal:  Can J Biochem       Date:  1969-03

5.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

6.  Tetrahydropapaveroline: formation in vivo and in vitro in rat brain.

Authors:  A J Turner; K M Baker; S Algeri; A Erigerio; S Garattini
Journal:  Life Sci       Date:  1974-06-01       Impact factor: 5.037

7.  Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-dopa in man.

Authors:  M Sandler; S B Carter; K R Hunter; G M Stern
Journal:  Nature       Date:  1973-02-16       Impact factor: 49.962

8.  [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].

Authors:  R Tissot; J M Gaillard; M Guggisberg; G Gauthier; J de Ajuriaguerra
Journal:  Presse Med       Date:  1969-04-05       Impact factor: 1.228

Review 9.  Disposition of catecholamine-derived alkaloids in mammalian systems.

Authors:  V E Davis; J L Cashaw; K D McMurtrey
Journal:  Adv Exp Med Biol       Date:  1975       Impact factor: 2.622

10.  Dopamine-derived tetrahydroisoquinoline alkaloids--inhibitors of neuroamine metabolism.

Authors:  A C Collins; J L Cashaw; V E Davis
Journal:  Biochem Pharmacol       Date:  1973-09-15       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.